Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05229601 · ClinicalTrials.gov registry record · Phase 1
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by HiFiBiO Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT05229601: Clinical Trial Phase 1 study, sponsored by HiFiBiO Therapeutics.
NCT05229601 is a Phase 1 study that was terminated before completion, run by HiFiBiO Therapeutics. The registered enrollment target is 31 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05229601, a Phase 1 study, was terminated before completion, sponsored by HiFiBiO Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and tolerability of HFB301001 in patients with advanced cancers. There are two parts in this study. During the escalation part, groups of participants will receive increasing doses until a safe and tolerable doses of HFB301001 is determined. During the expansion part, participants will take the dose of study drug that was determined from the escalation part of the study and will be assigned to a group based on the type of cancer they have.
Interventions
- DRUG HFB301001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2022-04-20 |
| Est. Completion | 2024-05-30 |
| Phase | Phase 1 |
Why NCT05229601 stopped before completion
NCT05229601 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (48% lower).
The record links to 0 conditions, and to 1 intervention - of which HFB301001 is the first listed.
NCT05229601 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05229601 about?
NCT05229601 is a clinical study titled "A Study of HFB301001 in Adult Patients With Advanced Solid Tumors". The purpose of this study is to test the safety and tolerability of HFB301001 in patients with advanced cancers. There are two parts in this study. During the escalation part, groups of participants will receive increasing doses until a safe and tolerable doses of HFB301001 is determined. During the...
What is the current status of trial NCT05229601?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2022-04-20. Estimated completion is 2024-05-30.
What interventions are being tested in trial NCT05229601?
The interventions under investigation include: HFB301001 (DRUG).
Who is sponsoring clinical trial NCT05229601?
This trial is sponsored by HiFiBiO Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05229601's enrollment target sits among peer trials
31 1322nd of 2000 higher than 669 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI